5 Best Peptides for Food Cravings

What to Know Before Choosing a Peptide for Food Cravings

Food cravings are not simply a willpower problem. They arise from two overlapping biological systems: the hypothalamus, which regulates physical hunger, and the brain's dopamine reward circuits, which create the motivational pull toward specific, pleasurable foods. The phenomenon users now call "food noise," that persistent mental preoccupation with food that makes any eating plan feel exhausting, originates in both systems at once. Peptides that engage both pathways are what make this field genuinely different from older appetite suppressants, which typically addressed only one.

Every compound in this guide earned its place because people are actually using it or actively discussing it for food cravings. That is the only test for inclusion. FDA-approved medications are here. Compounds available through licensed telehealth platforms are here. Investigational compounds that are not yet approved but have real trial data and active community discussion are here too. Evidence strength is stated honestly inside each entry rather than used as a filter to exclude compounds from the list. Where human trial data is strong and published, that is stated plainly. Where a compound is investigational and available only through clinical trials, that is stated plainly too.

The five entries are ordered by how prominently each appears in the published research and in real-world use, not as a verdict that one is better than another for any individual person. Tirzepatide and semaglutide sit at the top because they carry the deepest clinical evidence base and the most active user communities. Liraglutide follows as the first-generation benchmark with its own published record. Cagrilintide and retatrutide come after because they are still investigational, not because they are less worthy of attention. The right compound for any person depends on their health history, how they respond to each mechanism, and guidance from a prescribing clinician.

1. Tirzepatide: The Dual-Pathway Leader for Craving Elimination

Tirzepatide is the first peptide approved for weight management that activates two incretin hormone receptors simultaneously: the GLP-1 receptor and the GIP receptor. GLP-1, or glucagon-like peptide-1, is a gut hormone that signals fullness to the hypothalamus and to the brain's reward circuits. GIP, or glucose-dependent insulinotropic polypeptide, is a second incretin hormone that adds complementary appetite-suppressing signals through its own hypothalamic pathways, acting independently of the GLP-1 system. Engaging both receptors at once produces a more comprehensive dampening of food motivation than either pathway alone can deliver.

The practical result that users consistently describe is food noise simply going away. The anticipatory pull toward desserts, fast food, and habitual snacks becomes markedly quieter. Smaller portions feel naturally satisfying rather than disappointing, and the mental loop of thinking constantly about what to eat next loses its urgency. The clinical research is consistent with those accounts. In a 72-week Phase 3 trial, tirzepatide produced significantly lower Food Craving Inventory scores for sweets and high-fat fast foods compared to liraglutide, which served as the active comparator. Average weight loss in that trial reached roughly 21 percent, the highest recorded for any FDA-approved agent at the time. Functional MRI studies confirm that GLP-1 receptor agonists measurably reduce neural responses to food images in the amygdala, insula, orbitofrontal cortex, and putamen, the brain regions most associated with food wanting and habit-driven eating behavior.

Tirzepatide is FDA-approved under the brand name Zepbound for chronic weight management and under the brand name Mounjaro for type 2 diabetes. It is available by prescription through standard clinical practice and through licensed telehealth platforms. Administration is a weekly subcutaneous injection, typically starting at a low initial dose and escalating gradually to allow the body to adjust. The most common early side effects are nausea and bloating, which tend to ease as the dose stabilizes. A smaller subset of users report a more extreme suppression that tips from craving reduction into general food aversion, and some report anhedonia, a broader blunting of pleasure that extends beyond food. These responses vary considerably between individuals and are worth discussing with a prescribing physician before starting.

2. Semaglutide: The Most Extensively Studied Option

Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone GLP-1 and extends its effects far beyond the roughly two-minute natural half-life of the version the body produces. The injectable formulation has a half-life of approximately seven days, which is why a single weekly injection maintains continuous receptor activity. GLP-1 receptors are present in the hypothalamus, where they regulate the biological hunger drive, and in the ventral tegmental area and nucleus accumbens, the core structures of the brain's dopamine reward system. Semaglutide's action in those reward centers is what distinguishes it from traditional appetite suppressants: it reduces the "wanting" side of food motivation, the anticipatory drive toward palatable foods, while relatively preserving the ability to enjoy food once actually eating.

The clinical record here is the most substantial of any compound in this field. In a long-term analysis running to 104 weeks, semaglutide at the weight management dose produced significant and sustained improvements on Craving Control scores and reduced cravings across multiple food categories including savory, sweet, salty, spicy, dairy-rich, and starchy foods. Those craving improvements tracked closely with overall weight loss throughout the trial. Shorter controlled trials of 12 to 20 weeks showed marked reduction in preference for high-fat foods and diminished cravings for sweet and dairy-rich foods compared to placebo groups. An ongoing structured study, the CRAVE Study registered on ClinicalTrials.gov under identifier NCT06467604, is a 24-week observational trial monitoring semaglutide and tirzepatide users with the validated Food Craving Inventory-II instrument, adding further prospective data to what is already a deep evidence base.

Semaglutide is FDA-approved as Wegovy for chronic weight management and as Ozempic for type 2 diabetes, both as weekly injectable formulations. An oral tablet formulation, Rybelsus, is FDA-approved for type 2 diabetes. All three are available by prescription through standard clinical channels and licensed telehealth platforms. Compounded versions became widely available during drug shortage periods and carry meaningful additional risk, including dosing errors the FDA has formally flagged. The side effect profile largely mirrors tirzepatide: nausea is the most common complaint, particularly in the early weeks. Some users who have tried both report that the craving elimination feels somewhat less complete with semaglutide compared to tirzepatide's dual-mechanism approach, though for many people the effect is substantial and the long-term safety record is more established given the longer time on market.

3. Liraglutide: The First-Generation Benchmark

Liraglutide was the first GLP-1 receptor agonist approved specifically for weight management, and it remains a genuine option for people who cannot tolerate newer agents or who are working with a prescriber with a long track record using it. It acts through the same GLP-1 receptor mechanism as semaglutide, suppressing both the hypothalamic hunger drive and reward-circuit food motivation, but its shorter pharmacological half-life requires a daily injection rather than a weekly one. That difference in dosing frequency is a practical consideration that affects real-world adherence for many people.

The evidence for appetite and craving suppression is published and controlled. Buffet-style feeding studies showed liraglutide significantly reduced overall energy intake and consumption across all macronutrients, indicating broad appetite suppression rather than selective aversion to any one food type. It was used as the active comparator arm in the 72-week tirzepatide Phase 3 trial, which provides a useful direct comparison point: tirzepatide produced superior Food Craving Inventory scores in that head-to-head, but liraglutide's effects were real and clinically meaningful in their own right. It is FDA-approved as Saxenda for chronic weight management and as Victoza for type 2 diabetes, and it is available by prescription.

Where liraglutide fits best in the current landscape is for people who have a clinical reason to avoid the newer weekly agents, who have personal or medical management reasons for preferring daily dosing, or who are already stable on it and responding well. Users who have compared the experience directly to semaglutide or tirzepatide typically describe less complete elimination of food noise, which is consistent with what the trial data shows. That said, the reduction in craving-driven eating that liraglutide provides is meaningfully different from having no pharmacological support, and its longer time on market means the safety profile is well characterized.

4. Cagrilintide: The Amylin Pathway Approach to Combined Appetite Control

Cagrilintide belongs to a different hormone class from the GLP-1 compounds above. It is a long-acting amylin analog. Amylin is a pancreatic hormone co-secreted alongside insulin after meals, and it signals satiety through the area postrema in the brainstem and through the hypothalamus by pathways that are largely separate from the GLP-1 system. That non-overlapping mechanism is the scientific rationale for combining it with a GLP-1 agonist: two independent satiety systems activated simultaneously, addressing hunger from different biological angles at once.

The compound is being studied primarily as a combination therapy called CagriSema, which pairs cagrilintide with semaglutide, rather than as a standalone craving treatment. The combination is designed to produce additive appetite suppression by engaging the amylin pathway and the GLP-1 pathway in parallel. Cagrilintide also slows gastric emptying through its amylin mechanism, prolonging physical fullness and reducing the blood sugar oscillations that can drive rebound hunger after meals. The research rationale is scientifically sound, but the standalone evidence for craving reduction specifically is less developed than what exists for the GLP-1 agonists. Most available data comes from combination-therapy trials, and cagrilintide has not been approved by the FDA as either a standalone weight management agent or a craving-reduction therapy as of mid-2026.

Community discussion around cagrilintide is active. People following the obesity pharmacology pipeline are paying close attention to CagriSema combination results, and the compound is regularly discussed as a next-generation option particularly well suited to people who want a complementary mechanism layered on top of GLP-1 therapy. Access currently means enrolling in a clinical trial. Anyone encountering cagrilintide outside that channel should be aware that no approved formulation exists and that the evidence base, while genuinely promising, is still accumulating.

5. Retatrutide: The Triple-Receptor Candidate

Retatrutide activates three hormone receptors simultaneously: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. The GLP-1 and GIP components deliver the same dual-pathway craving suppression mechanism seen in tirzepatide. The glucagon receptor component adds a third action: it increases energy expenditure, promotes fat oxidation in the liver, and may contribute appetite-suppressing signals through the liver-brain axis. The combination of all three receptor targets makes it potentially the most metabolically comprehensive peptide in development for this goal.

Phase 2 trial data showed weight loss reaching roughly 24 percent in some participants, with some estimates from the data placing an upper range beyond that. User accounts from people who accessed it through clinical trials describe something close to complete elimination of food noise, a qualitative step above what most report from tirzepatide or semaglutide. The consistent descriptions across independent community sources include no desire for desserts or binge eating, removal of the dopamine pull from food cues, and the ability to eat smaller portions that feel genuinely satisfying. These accounts are informative, but they come from a self-selected population who specifically sought out an investigational compound, and that context matters for interpreting them.

Retatrutide is not FDA-approved as of mid-2026 and is in Phase 3 clinical trials, with completion expected around the same period and potential patient availability estimated around 2027. It is not available through any legitimate channel outside of clinical trial enrollment. The FDA has explicitly warned against purchasing unapproved versions for human use, and unregulated versions sold through gray-market research chemical channels carry risks that cannot be assessed, including unknown contaminants, inaccurate dosing, and a safety profile that remains incomplete because the full Phase 3 data does not yet exist. The early evidence is genuinely compelling, and the appropriate orientation is to follow the trial results closely and wait for the approved pathway.

How These Peptides Compare

Frequently Asked Questions

Do these peptides require a prescription?

The three FDA-approved compounds, tirzepatide, semaglutide, and liraglutide, all require a valid prescription from a licensed healthcare provider. Eligibility for the weight management indication typically depends on BMI thresholds or the presence of a weight-related health condition, though the specific criteria are determined by the prescribing clinician and the indication being treated. Cagrilintide and retatrutide are investigational and cannot be prescribed outside of clinical trial enrollment.

How do GLP-1 peptides actually reduce food cravings?

These compounds work at the level of the brain's reward system, not only in the stomach. GLP-1 receptors are present in the ventral tegmental area and nucleus accumbens, the structures responsible for dopamine-driven motivation toward rewarding stimuli including food. When those receptors are engaged, the anticipatory pull toward palatable foods is dampened. Functional MRI research has confirmed that semaglutide and related compounds measurably reduce neural responses to food images in regions including the amygdala and insula. The slowing of gastric emptying contributes physical fullness as well, but the craving reduction is primarily a brain-level effect.

Is there a difference between craving reduction and appetite suppression?

Yes, and the distinction matters when thinking about which compound to discuss with a prescriber. Appetite suppression reduces the general biological hunger signal, the physical drive to eat. Craving reduction targets the reward-driven motivation toward specific foods, the pull that makes someone want a particular snack even when they are not physically hungry. GLP-1 receptor agonists address both, but their action on the reward pathway is what distinguishes them from older suppressants that worked only on physical hunger. Users frequently describe the craving effect as the more transformative of the two.

What about peptides marketed for fat loss that are not GLP-1 agonists?

Compounds like CJC-1295, ipamorelin, and AOD-9604 are used in the peptide community for fat loss and body composition goals, but they work through growth hormone secretagogue pathways rather than the gut-brain appetite axis. No meaningful published evidence supports their use for reducing food cravings or food noise. The underlying mechanisms simply do not intersect with the hunger and reward pathways that drive cravings. When craving reduction is the primary goal, the evidence consistently points to GLP-1 receptor agonists as the relevant compound class.

Are compounded versions of these peptides a safe alternative?

Compounded semaglutide and tirzepatide became widely available during drug shortage periods, but they carry risks that the FDA-approved pharmaceutical formulations do not. The FDA has reported hospitalizations linked to dosing errors in compounded semaglutide and has issued explicit warnings against purchasing products labeled for research purposes or as research chemicals for human use. Compounded versions are not subject to the same quality control, purity verification, or dosing accuracy standards as approved pharmaceutical products. If cost or access is the concern, the more appropriate path is a conversation with a licensed prescribing physician or telehealth provider about available options rather than turning to unregulated sources.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and user-reported real-world use of peptides for food cravings in one place.